IMMH002, a selective S1P receptor agonist which is developed by a research group of Institute of Materia Medica of Chinese Academy of Medical Sciences, can selectively excite S1P1 receptor subtypes, while show a weak activity for exciting S1P3 receptor subtypes and less side effects on the heart; and its short half-life lead to more efficient and rapid reversible inhibition for lymphocytes exhibit transport. As a new structural and highly selective S1P1 receptor agonist, IMMH002 has applied for a domestic p...